Alosetron - CAS 122852-42-0
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Alosetron
Catalog Number:
122852-42-0
Synonyms:
ALOSETRON;ALOSETRON2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one
CAS Number:
122852-42-0
Description:
Alosetron, an effective 5-HT3 receptor antagonist, could be commonly used against irritable bowel syndrome.
Molecular Weight:
294.36
Molecular Formula:
C17H18N4O
Quantity:
Grams-Kilos
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C
InChI:
InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19)
InChIKey:
JSWZEAMFRNKZNL-UHFFFAOYSA-N
Targets:
5-HT Receptor
Chemical Structure
CAS 122852-42-0 Alosetron

Related 5-HT Receptor Products


CAS 122883-93-6 Ziprasidone Hydrochloride

Ziprasidone Hydrochloride
(CAS: 122883-93-6)

The hydrochloride salt form of Ziprasidone which is an antagonism of both serotonin and dopamine receptor and could be effective against schizophrenia.

AVN-211
(CAS: 1173103-84-8)

This active molecular is a Selective 5-HT6 Receptor antagonist, for the treatment of Alzheimer's Disease under development by by Avineuro Pharmaceuticals. AVN-2...

CAS 316-81-4 Thioproperazine

Thioproperazine
(CAS: 316-81-4)

Thioproperazine is a potent neuroleptic with antipsychotic properties, for the treatment of all types of acute and chronic schizophrenia, including those which ...

CAS 261901-57-9 SB-269970 hydrochloride

SB-269970 hydrochloride
(CAS: 261901-57-9)

SB269970 HCl is a hydrochloride salt form of SB-269970, which is a 5-HT7 receptor antagonist with pKi of 8.3, exhibits >50-fold selectivity against other recept...

GYKI-46903 HCl
(CAS: 142999-59-5)

GYKI-46903 is a Muscarinic M3 receptor and Serotonin 3 receptor antagonist. In displacement studies, the pIC50 values of GYKI-46903 against [3H]granisetron bind...

CAS 59729-32-7 Citalopram hydrobromide

Citalopram hydrobromide
(CAS: 59729-32-7)

Citalopram Hydrobromide is an inhibitor of serotonin (5-HT) uptake used as an antidepressant.

CAS 111974-69-7 Quetiapine

Quetiapine
(CAS: 111974-69-7)

Quetiapine, an thiazepin-analogue of Clozapine, could be effective in the treatment for schizophrenia and major depressive disorder for behaving as a 5HT-2 and ...

CAS 112885-41-3 Mosapride

Mosapride
(CAS: 112885-41-3)

Mosapride, a selective agonist of 5-HT4 receptor, could be used as a astroprokinetic agent. It is also found to be a 5-HT3 receptor antagonist.

CAS 269718-84-5 Pardoprunox

Pardoprunox
(CAS: 269718-84-5)

Pardoprunox, also called as SLV308 or DU-126891, is a D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A rec...

LY 302148
(CAS: 182564-47-2)

LY 302148 is a 5-HT1F receptor agonist with potential for migraine therapeutics.

CAS 158930-09-7 Frovatriptan Succinate

Frovatriptan Succinate
(CAS: 158930-09-7)

Thesuccinate salt form of Frovatriptan, a carbazole derivative, has been found to be a 5-HT receptor agonist that could be used as an antimigraine agent.

CAS 109889-09-0 Granisetron

Granisetron
(CAS: 109889-09-0)

Granisetron is an antagonist of serptpmom 5-HT3 receptor and could be used to relieve the nausea and vomiting symptom after receving chemotherapy by decreasing ...

CAS 1049747-87-6 SB-242084 HCl salt

SB-242084 HCl salt
(CAS: 1049747-87-6)

SB-242084 is a psychoactive drug and research chemical which acts as a selective antagonist for the 5HT2C receptor. It can increase the effectiveness of the sel...

CAS 115956-13-3 Dalasetron Mesylate

Dalasetron Mesylate
(CAS: 115956-13-3)

The mesylate salt form of Dolasetron which is a pseudopelletierine derivative and could be used to relieve the nausea and vomiting caused by chemotherapy for be...

CAS 193611-72-2 BRL-15572

BRL-15572
(CAS: 193611-72-2)

BRL-15572 displays high affinity and selectivity for h5-HT1D receptors. BRL-15572 has 60-fold higher affinity for h5-HT1D than 5-HT1B receptors.

CAS 133025-23-7 Way 100135

Way 100135
(CAS: 133025-23-7)

Way 100135 is a selective 5-HT1A receptor antagonist originated by Wyeth with IC50 value of 15 nM. IC 50 values for 5-HT1B, 1C, 2,α1, α2 and D2 receptors are ov...

CAS 521-78-8 Trimipramine Maleate

Trimipramine Maleate
(CAS: 521-78-8)

Trimipramine Maleate is a tricyclic antidepressant for the treatment of depression and depression accompanied by anxiety.

CAS 137328-52-0 LY 215840

LY 215840
(CAS: 137328-52-0)

LY 215840 is a potent antagonist of both Serotonin 2A receptor and Serotonin 7 receptor. It can reduce stimulatory effect of serotonin on aldosterone secretion ...

CAS 123040-16-4 Azasetron hydrochloride

Azasetron hydrochloride
(CAS: 123040-16-4)

Azasetron HCl is a selective 5-HT3 receptor antagonist with IC50 of 0.33 nM used in the management of nausea and vomiting induced by cancer chemotherapy.

Naratriptan D3 Hydrochloride
(CAS: 1190021-64-7)

The hydrochloride salt form of isotope labelled Naratriptan which is a selective 5-HT1 receptor agonist and could be used against migraine headaches.

Reference Reading


1.Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome.
Lacy BE1. Int J Gen Med. 2016 Feb 11;9:7-17. doi: 10.2147/IJGM.S93698. eCollection 2016.
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders worldwide. The economic impact of IBS on the health care system is substantial, as is the personal impact on patients. Patients with diarrhea-predominant IBS (IBS-D) comprise a substantial proportion of the overall IBS population. Primary care providers are often the first point of contact for patients with IBS-D and can accurately diagnose IBS after a careful history and examination without extensive diagnostic tests. Several pharmacologic treatments (eg, loperamide, alosetron, and antidepressants) and non-pharmacologic treatments (eg, dietary modification and probiotics) are available for IBS-D, but restrictions on use (eg, alosetron) or the lack of controlled trial data showing reductions in both global and individual IBS-D symptoms (eg, bloating, pain and stool frequency) emphasize the need for alternative treatment options. Two newer medications (eluxadoline and rifaximin) were approved in May 2015 for the treatment of IBS-D, and represent new treatment options for this common gastrointestinal condition.
2.Sex-related differences in small intestinal transit and serotonin dynamics in high-fat-diet-induced obesity in mice.
France M1, Skorich E1, Kadrofske M2, Swain GM1,3, Galligan JJ1,4. Exp Physiol. 2016 Jan 1;101(1):81-99. doi: 10.1113/EP085427. Epub 2015 Oct 28.
NEW FINDINGS: What is the central question of this study? Are the sex differences in the effects of obesity on serotonin signaling mechanisms in the small intestine? What is the main finding and its importance? We demonstrate that small intestinal transit is altered in male and female obese mice. We found sex differences in intestinal 5-HT signalling in the jejunum of male and female obese mice that may underlie the altered intestinal transit. Our results reveal important sex differences in 5-HT-linked intestinal dysfunction in obesity. Obesity alters gastrointestinal (GI) motility and 5-HT signalling. Altered 5-HT signalling disrupts control of GI motility. Levels of extracellular 5-HT depend on enterochromaffin (EC) cell release and serotonin transporter (SERT) uptake. We assessed GI transit and 5-HT signalling in the jejunum of normal and obese mice. Male and female mice were fed a control diet (CD; 10% of kilocalories as fat) or a high-fat diet (HFD; 60% of kilocalories as fat).
3.Novel Therapies in IBS-D Treatment.
Nee J1, Zakari M2, Lembo AJ2. Curr Treat Options Gastroenterol. 2015 Dec;13(4):432-40. doi: 10.1007/s11938-015-0068-5.
OPINION STATEMENT: Irritable bowel syndrome (IBS) is a common gastrointestinal disease characterized by abdominal pain and change in bowel habits. IBS diarrhea predominant (IBS-D), which is arguably the most common subset of IBS, is also associated with rectal urgency, increased frequency, abdominal bloating, and loose to watery stools. Current treatments for diarrhea include mu-opioid agonists (i.e., loperamide, lomotil) and bile acid sequestrants (i.e., cholestyramine) while treatments for abdominal pain include antispasmodics (i.e., hyoscyamine, dicyclomine) and tricyclic antidepressants (i.e., amitriptyline). There are currently 3 FDA-approved treatments for IBS-D, which have been shown to improve both abdominal pain and diarrhea. Alosetron was initially approved by FDA 2000; however, its use is now limited to women with severe IBS-D symptoms refractory to other treatment. Eluxadoline, a mixed mu-opioid agonist, and rifaximin, a broad spectrum gut specific antibiotic, were both FDA approved in 2015.
4.Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
Fukudo S1, Kinoshita Y2, Okumura T3, Ida M4, Akiho H5, Nakashima Y6, Nishida A7, Haruma K8. Gastroenterology. 2016 Feb;150(2):358-366.e8. doi: 10.1053/j.gastro.2015.10.047. Epub 2015 Nov 6.
BACKGROUND & AIMS: Previous studies have indicated that serotonin-3-receptor antagonists might have a sex-specific effect in patients with irritable bowel syndrome with diarrhea (IBS-D). Alosetron has been approved for the treatment of only women, and ramosetron has been approved for the treatment for only men. We performed a randomized, placebo-controlled, phase 3 study to determine whether ramosetron reduces symptoms of IBS-D in women.